MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202541134627 A) filed by Sree Balaji Dental College And Hospital, Chennai, Tamil Nadu, on Dec. 31, 2025, for 'non-invasive salivary glutamate & opiorphin assay for assessment of symptomatic irreversible pulpitis pain.'
Inventor(s) include Dr. Mathangi. R; Dr. N. Aravindha Babu; and Dr. S. Bhuminathan.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a non-invasive diagnostic method for objectively assessing pain associated with symptomatic irreversible pulpitis in human subjects diagnosed with Type 2 Diabetes Mellitus. The method involves obtaining unstimulated whole saliva, quantifying glutamate and opiorphin levels using enzyme-linked immunosorbent assay (ELISA) and immunoassay techniques, and comparing the quantified biomarker levels along with the pain threshold ranges.,. This invention thus enables reproducible, objective, and clinically actionable pain measurement without reliance on subjective self-reporting."
Disclaimer: Curated by HT Syndication.
